Liquidia (NASDAQ:LQDA) Receives Market Perform Rating from Lifesci Capital

Key Points

• Lifesci Capital reiterated a “Market Perform” rating on Liquidia and set a $90 price target, implying 13.82% upside from the prior close. Analysts’ consensus rating is “Moderate Buy,” with an average target price of $90.
• Liquidia shares fell $8.98 to $79.07, despite reporting $171.68 million in quarterly revenue—well above estimates—while EPS of $0.74 narrowly missed the $0.76 consensus.
• Insiders sold significant shares: company insiders sold 1.78 million shares worth approximately $124.4 million over the past three months, although institutional and hedge-fund ownership stands at 64.54%.

Liquidia (NASDAQ:LQDA - Get Free Report)'s stock had its "market perform" rating restated by research analysts at Lifesci Capital in a research note issued on Wednesday,Benzinga reports. They presently have a $90.00 target price on the stock. Lifesci Capital's price target would indicate a potential upside of 13.82% from the stock's previous close.

LQDA has been the topic of several other reports. BTIG Research boosted their target price on Liquidia from $59.00 to $109.00 and gave the company a "buy" rating in a research note on Monday, June 22nd. Bank of America reissued a "neutral" rating and set a $79.00 price objective (up from $64.00) on shares of Liquidia in a report on Monday, June 29th. HC Wainwright set a $36.00 target price on Liquidia in a report on Friday, July 24th. Stephens set a $130.00 price target on Liquidia in a research report on Friday, July 24th. Finally, Royal Bank Of Canada set a $130.00 price target on shares of Liquidia in a report on Friday, July 24th. Two research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, two have issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, Liquidia has an average rating of "Moderate Buy" and a consensus target price of $90.00.

Liquidia Stock Performance

Shares of Liquidia stock traded down $8.98 on Wednesday, reaching $79.07. 3,040,638 shares of the company traded hands, compared to its average volume of 1,774,534. The company has a 50 day moving average of $77.76 and a 200 day moving average of $54.51. The company has a debt-to-equity ratio of 1.18, a current ratio of 2.22 and a quick ratio of 2.03. Liquidia has a 52 week low of $21.15 and a 52 week high of $93.61. The firm has a market capitalization of $7.03 billion, a PE ratio of 564.83 and a beta of 0.58.

Liquidia (NASDAQ:LQDA - Get Free Report) last posted its quarterly earnings results on Wednesday, August 12th. The company reported $0.74 EPS for the quarter, missing analysts' consensus estimates of $0.76 by ($0.02). Liquidia had a return on equity of 46.82% and a net margin of 7.74%.The company had revenue of $171.68 million during the quarter, compared to the consensus estimate of $168.48 million. During the same period last year, the firm posted ($0.49) EPS. The company's revenue for the quarter was up 1842.1% compared to the same quarter last year. Equities analysts forecast that Liquidia will post 3.02 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director Stephen M. Bloch sold 242,269 shares of the firm's stock in a transaction on Thursday, June 11th. The shares were sold at an average price of $70.43, for a total transaction of $17,063,005.67. Following the sale, the director owned 1,176,184 shares in the company, valued at approximately $82,838,639.12. This trade represents a 17.08% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Paul B. Manning sold 200,000 shares of Liquidia stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $63.91, for a total transaction of $12,782,000.00. Following the sale, the director directly owned 716,311 shares of the company's stock, valued at $45,779,436.01. This represents a 21.83% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 1,781,861 shares of company stock worth $124,407,112 in the last three months. Insiders own 25.60% of the company's stock.

Hedge Funds Weigh In On Liquidia

Hedge funds and other institutional investors have recently modified their holdings of the company. Bank of New York Mellon Corp purchased a new position in shares of Liquidia during the 2nd quarter valued at about $29,694,000. Handelsbanken Fonder AB purchased a new stake in Liquidia in the second quarter worth approximately $1,993,000. Fulcrum Equity Management purchased a new stake in Liquidia in the second quarter worth approximately $399,000. Fluent Financial LLC bought a new position in Liquidia during the second quarter valued at approximately $287,000. Finally, FNY Investment Advisers LLC purchased a new position in shares of Liquidia during the second quarter worth approximately $1,395,000. 64.54% of the stock is currently owned by hedge funds and other institutional investors.

More Liquidia News

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: YUTREPIA sales accelerated. Net product sales reached approximately $170.4 million in the second quarter, up 31% from the first quarter. Liquidia reported roughly 5,900 unique prescriptions and more than 5,000 patients treated since the product launched in June 2025. Liquidia Corporation Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Profitability and cash generation improved. Liquidia posted $171.7 million in revenue, $74.7 million in net income and $96.3 million in adjusted EBITDA, marking its fourth consecutive quarter of increasing profitability. Cash and equivalents rose to approximately $284.2 million from $190.7 million at the end of 2025. Liquidia Q2 Net Income Reaches $74.7 Million As YUTREPIA Sales Rise
• Positive Sentiment: Management maintained its long-term growth outlook. Liquidia reaffirmed its target of more than $1 billion in net revenue in 2027 and is advancing 10 clinical studies involving YUTREPIA and the L606 inhaled treprostinil program.
• Neutral Sentiment: Institutional interest remains mixed but generally supportive. Recent filings showed major investors including BlackRock and State Street adding shares, although some funds reduced their positions.
• Negative Sentiment: Adjusted expectations contributed to the selloff. Diluted EPS of $0.74 was slightly below the approximately $0.76 analyst consensus cited by several reports, despite revenue exceeding expectations. Another estimate source placed consensus at $0.70, highlighting differences among analyst forecasts. Liquidia shares fall after second-quarter earnings miss despite revenue growth
• Negative Sentiment: Spending is increasing. Research and development expenses rose to $17.2 million from $6.0 million a year earlier as Liquidia funds the Phase 3 L606 program. The company’s elevated valuation also leaves less room for disappointing results.
• Negative Sentiment: Insider selling is a potential overhang. Reported insider activity over the past six months consisted overwhelmingly of sales, including transactions by senior executives, with only one reported purchase.

About Liquidia

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company's lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source